[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ascites\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ascites":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,45,72,98,128,171,203,231,255,280,306,331,353,373],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100505916","phase-2-high-dose-albumin-in-refractory-ascites-100505916",false,"NCT05867602","High Dose Albumin in Refractory Ascites","Clinical Efficacy of High-dose Albumin Administration Versus Standard Dose in Patients With Advanced Cirrhosis: Open Label Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. patients diagnosed with liver cirrhosis.\n3. Refractory ascites which is defined as ascites failing to resolve after maximum tolerable dose of diuretics, and usually require frequent paracentesis.\n\nExclusion Criteria:\n\n1. Patients \\\u003C 18y\n2. patients with no history of liver cirrhosis\n3. patients with refractory ascites but have transjagular intrahepatic portosystemic shunts (TIPS) with previous 3 months\n4. Patients with ascites due to other causes, including cardiac, malignant","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Advanced cirrhosis with complications is a serious problem imposing a heavy financial burden on health care system. Moreover, ascites is associated with increase in mortality rates among cirrhotic patients. Ascites pathogenesis is multifactorial including: portal hypertension; splanchnic and peripheral arterial vasodilation; and neurohumoral activation. Current management strategies include dietary sodium restriction and diuretic therapy, however, this strategy put patients at the risk of intravascular volume depletion, renal impairment, hepatic encephalopathy and hyponatremia. Moreover, around 10% of patients do not respond to this strategy (termed: diuretics resistant) with 50% of them die within 6 months. This sub-group is managed by frequent large volume paracentesis along with intravenous albumin administration and are usually considered for liver transplantation (LT) and TIPS. Nonetheless, Frequent paracentesis increases the risk of infection, bleeding, bowel perforation, paracentesis-induced circulatory dysfunction (PICD) and renal dysfunction in this sub-group of patients. The beneficial effect of human albumin might result from blood volume expansion tapering activated vasoconstrictor and sodium-retaining systems improving renal perfusion, hence regular infusion of albumin may be beneficial to prevent development of ascites and to improve survival. The positive effects of albumin are supported by previous studies; Romanelli et al, showed a significant increase in survival rate among cirrhotic patients with ascites when compared to those who did not receive albumin. Moreover, a randomized multicenter open label trial published in lancet last year, demonstrated that long term albumin administration improved 18-month survival, decreased the use of paracentesis and decrease in the incidence of cirrhosis related complications among cirrhotic patients with ascites. As of today, there's a limited use of regular high dose albumin in cirrhotic patients with ascites in US, despite being used elsewhere in the world as previously stated.\n\nThe investigators wish to study long-term efficacy of human albumin administration in patients with decompensated cirrhosis to assess safety and efficacy, and prevention of complications of cirrhosis.",[26],"Ascites",[28,29,30,31],"refractory ascites","liver cirrhosis","HRS","High dose albumin","RECRUITING","2026-06-26",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2019-03-25",{"date":40,"type":20},"2027-06-25",{"name":42,"class":43},"Baylor College of Medicine","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100643884","ultrasound-assessment-of-diaphragmatic-structure-and-function-in-patients-with-liver-cirrhosis-a-point-of-care-tool-for-predicting-complications-and-sarcopenia-in-limited-resource-settings-100643884","NCT07667608","Ultrasound Assessment of Diaphragmatic Structure and Function in Patients With Liver Cirrhosis: A Point-of-Care Tool for Predicting Complications and Sarcopenia in Limited Resource Settings","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Confirmed diagnosis of liver cirrhosis based on clinical, biochemical, histological, or imaging criteria.\n3. Ability to provide written informed consent in Arabic or English.\n4. For Subgroup A: clinical indication for large-volume paracentesis with an ascitic volume of ≥5 liters.\n5. For Subgroup B: confirmed hepatic hydrothorax or confirmed absence of pleural effusion on ultrasound or chest X-ray.\n6. For Subgroup C: radiologically confirmed HCC by triphasic CT or MRI according to EASL\u002FAASLD diagnostic criteria, with available CT imaging for L3 SMI analysis.\n\nExclusion Criteria:\n\n1. Significant pre-existing primary pulmonary disease (e.g., moderate-to-severe COPD defined as FEV1\u002FFVC \\\u003C70% with FEV1 \\\u003C60% predicted, interstitial lung disease, pulmonary fibrosis) that independently affects diaphragmatic mechanics.\n2. Recent thoracic surgery, thoracocentesis within the preceding 72 hours, or thoracic trauma.\n3. Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, Guillain-Barré syndrome) independently affecting diaphragmatic function.\n4. Active mechanical ventilation at time of enrollment.\n5. Pregnancy.\n6. Inability to achieve adequate ultrasound acoustic windows (e.g., due to extreme obesity or surgical dressings).\n7. Contraindications to paracentesis in Subgroup A (e.g., disseminated intravascular coagulation, bowel obstruction).\n8. Prior or planned liver transplantation within the study period, which would confound longitudinal follow-up.\n9. Refusal or inability to provide informed consent.",true,{"count":53,"type":20},120,"OBSERVATIONAL","The goal of this observational study is to learn how liver cirrhosis affects the diaphragm, the main muscle used for breathing, in adults. The study will measure diaphragmatic thickness, thickening fraction, and excursion using bedside ultrasound and compare these values between patients with cirrhosis and healthy volunteers. The main questions it aims to answer are:\n\nDo patients with cirrhosis show reduced diaphragmatic function compared to healthy adults?\n\nDoes removal of ascitic fluid by paracentesis improve diaphragmatic mechanics?\n\nCan ultrasound measurements of the diaphragm serve as a reliable non-invasive marker of sarcopenia when compared to CT scans?\n\nParticipants will:\n\nUndergo diaphragmatic ultrasound during quiet and deep breathing\n\nProvide clinical and laboratory data related to liver disease severity\n\nIn some cases, have ultrasound repeated before and after paracentesis\n\nFor patients with hepatocellular carcinoma, CT scans will be analyzed to measure muscle mass",[57,26,58,59,60,61],"Cirrhosis of the Liver","Pleural Effusion Disorder","Hepatocellular Carcinoma (HCC)","Sarcopenia","Diaphragm Movement","NOT_YET_RECRUITING","2026-06-19",{"date":65,"type":36},"2026-06-25",{"date":67,"type":20},"2026-08-10",{"date":69,"type":20},"2027-12-10",{"name":71,"class":43},"Assiut University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":51,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100643532","gut-leakage-in-dengue-100643532","NCT07602920","Gut Leakage' in Dengue","Gut Leakage and Sonographic Abdominal Changes in Hospitalized Dengue Patients: an Observational Study","GLiD","Inclusion Criteria:\n\nDengue participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Diagnosed as a case of Dengue on the basis of clinical features and positive NS1 antigen and\u002For IgM dengue antibody\n* Hospitalized in medicine or dengue ward in Chittagong Medical College Hospital.\n* Enrolled within 24 hours of hospitalization.\n\nHealthy participants\n\n* Participant\u002F legally authorised representative willing and able to give informed consent for participation in the study.\n* Male or Female, adults ≥18 years\n* Clinically healthy with no acute or chronic illness\n* Attendant of a dengue patient (not a patient)\n\nExclusion Criteria:\n\nDengue participants\n\n* Unable to provide consent or participate in follow-up procedures\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n\nHealthy participants\n\n* Unable to provide consent\n* Known chronic gastrointestinal (GI) disease affecting intestinal permeability (IBD, celiac disease), chronic liver disease, active chronic diarrhoea, short bowel loop syndrome, recent (\\\u003C3 months) major GI surgery.\n* Immunosuppression (for example chemotherapy, high-dose steroids), advanced chronic kidney disease, decompensated heart failure.\n* Drugs that can alter the level of biomarkers in blood like metformin, statin, probiotics, steroid within last 48 hours of hospitalization.\n* Pregnancy\n* History of current or recent dengue or other arbo viral infection",{"count":81,"type":20},190,"Dengue infections are imposing an increasing global burden of disease, particularly in tropical countries such as Bangladesh. The World Health Organization (WHO) has identified Dengue virus as a priority pathogen for the development of medical counter measures because of the high risk of it causing a Public Health Emergency of Intenational Concern (PHEIC). Warning signs for severe dengue, associated with mortality, include gastrointestinal features including abdominal pain, vomiting, and diarrhoea. Multiple alterations may occur in in the gastrointestinal tract that could lead to damaging of the gastrointestinal wall and gut leakage, the translocation of gut metabolites into the bloodstream. Study team hypothesize that gut leakage initiates inflammatory processes underlying the further development of severe dengue, including features associated with plasma leakage.\n\nThis study aims to investigate intestinal barrier dysfunction (gut leakage) in dengue infection by detecting the translocation of gut-derived bacteria and their products (Lipopolysaccharides, LPS binding protein, sCD14, I-Fatty Acid Binding Protein) into the bloodstream. Study team will recruit hospitalized adult dengue patients (18 years and older) presenting with warning signs or severe disease in a tertiary care public hospital at Chattogram, Bangladesh. Circulating biomarkers indicative of gut permeability and microbial translocation will be measured to assess their presence and association with disease severity.\n\nAbdominal ultrasonography will be performed to characterize gastrointestinal alterations and determine their correlation with biochemical markers of gut leakage and clinical severity. In addition, study team will analyze the gut bacteriome from stool\u002F rectal swab of these patients to explore whether dengue infection induces compositional changes in intestinal microbiota and whether such alterations are linked to gut leakage or disease progression.",[84,85,86,26,87,88],"Dengue","Dengue Hemorrhagic Fever","Intestinal Disease","Dengue With Warning Signs","Gut Microbiome","2026-06-08",{"date":91,"type":36},"2026-06-10",{"date":93,"type":20},"2026-07-01",{"date":95,"type":20},"2028-01-31",{"name":97,"class":43},"University of Oxford",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":44},"100561776","free-fluid-detection-with-telementored-efast-100561776","NCT06594562","Free Fluid Detection With Telementored eFAST","Telementored eFAST in Patients Post-Liver Surgery: A Study of Diagnostic Accuracy for Detection of Free Fluid","Inclusion Criteria:\n\nPatients who have undergone laparoscopic liver surgery at the Oslo university hospital and are within 72 post-surgery\n\nExclusion Criteria:\n\nAllergy to ultrasound gel. Patients colonized with ESBL, MRSA and VRE will be excluded due to infection control. Significant postoperative pain that can exacerbated by probe pressure.",{"count":106,"type":20},40,[108],"NA","This feasibility study will evaluate the accuracy of telementored eFAST (Extended Focused Assessment with Sonography in Trauma) in detecting abdominal free fluid in patients who have recently undergone liver surgery. The primary goal is to determine how well the remote-guided ultrasound can identify fluid accumulation compared to conventional ultrasound performed by a radiologist. Participants in this study will be examined with ultrasound, supported in real-time by a remote expert, to assess its accuracy and other relevant performance metrics.",[111,26,112,113],"Hemoperitoneum","Intra-Abdominal Fluid Collection","Postoperative Complications",[115,116,117,118],"Teleultrasound","eFAST","Telemedicine","Ultrasound","2026-05-12",{"date":121,"type":36},"2026-05-15",{"date":123,"type":36},"2025-06-18",{"date":125,"type":20},"2026-10-01",{"name":127,"class":43},"Oslo University Hospital",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":21,"phases":138,"briefSummary":140,"conditions":141,"keywords":147,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":44},"100633026","phase-4-apixaban-pk-trial-preventing-portal-hypertension-complications-in-cirrhosis-100633026","NCT07521332","Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis","Apixaban Plus Carvedilol to Prevent Portal Hypertension Complications in Cirrhosis: A Randomized Single-Blind Placebo-Controlled Trial at AIMS, Hyderabad, Pakistan","APIXABAN-PK","Inclusion Criteria:\n\n1. Adults aged ≥18 years with diagnosed cirrhosis (any etiology), confirmed by histology, transient elastography (≥12.5 kPa), or consistent clinical\u002Fimaging findings.\n2. Evidence of portal hypertension, defined by:\n\n   Clinical: presence of varices on endoscopy, ascites, or splenomegaly with thrombocytopenia.\n3. Compensated or early decompensated cirrhosis (Child-Pugh B 7-10), with stable liver function defined as no change in Child-Pugh score \\>1 point in the preceding 3 months.\n4. Screening esophagogastroduodenoscopy (EGD) performed within 6 months prior to enrollment. Patients with high-risk varices (large varices, red wale signs, or history of variceal bleeding) must undergo endoscopic variceal band ligation to obliteration before randomization.\n5. Able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Active gastrointestinal bleeding within 6 weeks prior to enrollment.\n2. High bleeding risk:\n\n   * Platelet count \\\u003C50,000\u002FµL at baseline\n   * INR \\>1.8 (or \\>2.0 if secondary to cirrhosis without additional coagulopathy)\n   * Active peptic ulcer disease\n   * History of intracranial hemorrhage or hemorrhagic stroke\n   * Known bleeding diathesis\n3. Severe renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²) or on dialysis.\n4. Child-Pugh class C or Child-Pugh score ≥10.\n5. History of hypersensitivity to apixaban or carvedilol.\n6. Pregnancy, breastfeeding, or unwillingness to use effective contraception during the study period.\n7. Concurrent anticoagulant or antiplatelet therapy (including aspirin, clopidogrel, warfarin, or other DOACs) that cannot be safely discontinued. A washout period of at least 5 half-lives is required before randomization.\n8. Use of NSAIDs, SSRIs, or other medications that significantly increase bleeding risk, unless approved by the PI with clear risk-benefit justification.\n9. Active hepatocellular carcinoma (HCC) outside Milan criteria or with vascular invasion.\n10. Current or planned liver transplantation.",{"count":137,"type":20},220,[139],"PHASE4","The APIXABAN-PK trial is a prospective, randomized, single-blind, placebo-controlled study designed to evaluate the efficacy and safety of apixaban in combination with carvedilol versus placebo with carvedilol in preventing portal hypertension-related complications in patients with cirrhosis. Conducted at the Gastroenterology and Hepatology Department and Clinical Trials Unit (CTU) of Asian Institute of Medical Sciences (AIMS) Hospital, Hyderabad, Pakistan, the trial will enroll eligible cirrhotic patients with portal hypertension. Participants will be followed for 12 months to monitor hepatic decompensation events, variceal bleeding, portal vein thrombosis, and mortality, while safety and tolerability of apixaban will be closely assessed. This study aims to provide local evidence for apixaban use in cirrhosis management in Pakistan.",[142,143,26,144,145,146],"Cirrhosis","Esophageal and Gastric Varices","Hepatic Encephalopathy","Portal Vein Thrombosis","Portal Hypertension",[148,149,150,151,152,153,154,155,156,157,158,159,160,161],"apixaban","carvedilol","cirrhosis","portal hypertension","direct oral anticoagulant","variceal bleeding","hepatic decompensation","portal vein thrombosis","randomized controlled trial","Pakistan","Factor Xa Inhibitor","non-selective beta-blocker","prevention","liver disease","2026-04-03",{"date":164,"type":36},"2026-04-09",{"date":166,"type":36},"2026-04-01",{"date":168,"type":20},"2028-04-01",{"name":170,"class":43},"Asian Institute Of Medical Sciences",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":178,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":44},"100626443","phase-1-intraperitoneal-sk-nk-cell-injection-for-advanced-ovarian-cancer-with-massive-ascites-100626443","NCT07435701","Intraperitoneal SK-NK Cell Injection for Advanced Ovarian Cancer With Massive Ascites","A Single-Arm, Open-Label Phase I\u002FII Clinical Trial of Intraperitoneal Perfusion of SK-NK Cell Injection for the Treatment of Advanced Ovarian Cancer Patients With Massive Ascites","Inclusion Criteria:\n\nVoluntarily sign the written Informed Consent Form (ICF) and be able to comply with study procedures and follow-up.\n\nFemale, aged 18 to 75 years. ECOG performance status of 0 to 2. Histologically or cytologically confirmed advanced ovarian cancer. Participants must have failed at least two lines of standard therapy (disease progression or intolerance), have no standard therapy available, or be unable to receive standard therapy for other reasons .\n\nComplicated by massive malignant ascites, defined as a volume of ≥ 2000 mL indicated by Ultrasound or CT.\n\nExpected survival time ≥ 3 months.\n\nAdequate organ function (no blood transfusion, cell growth factors, etc., within 14 days prior to enrollment), defined as:\n\nNeutrophils (ANC) ≥ 1.0×10\\^9\u002FL Platelets (PLT) ≥ 80×10\\^9\u002FL Hemoglobin (Hb) ≥ 80 g\u002FL Total Bilirubin (TBIL) ≤ 1.5×ULN (≤ 3×ULN for Gilbert's syndrome or liver metastasis) ALT and AST ≤ 2.5×ULN (≤ 5×ULN if liver metastasis is present) INR ≤ 1.5×ULN and APTT ≤ 1.5×ULN (unless on anticoagulant therapy) Creatinine clearance ≥ 60 mL\u002Fmin (calculated by Cockcroft-Gault formula) Toxicities from prior therapies must have recovered to ≤ Grade 1 (except for alopecia and ≤ Grade 2 neurotoxicity caused by chemotherapy) .\n\nExclusion Criteria:\n\nPrior receipt of other cell therapies. Presence of loculated (septated) ascites indicated by CT or Ultrasound. Receipt of any systemic anti-tumor therapy (including chemotherapy, targeted therapy, etc.) within 3 weeks prior to intraperitoneal perfusion.\n\nReceipt of Traditional Chinese Medicine (herbal) with anti-tumor indications within 3 weeks prior to intraperitoneal perfusion.\n\nReceipt of systemic corticosteroids (≥ 10 mg\u002Fday prednisone or equivalent) or other immunosuppressive medications within 2 weeks prior to intraperitoneal perfusion (inhaled, topical, or physiologic replacement doses are allowed).\n\nMajor surgery within 4 weeks prior to screening or planned major surgery during the study period.\n\nHistory of other malignancies within 5 years (except for cured local tumors with low risk of recurrence, such as non-melanoma skin cancer).\n\nHistory of active or suspected autoimmune or inflammatory disease. History of organ transplantation or hematopoietic stem cell transplantation.\n\nPresence of active infection, including:\n\nActive Hepatitis B (HBsAg positive and HBV-DNA \\> 1000 copies\u002FmL) Active Hepatitis C (HCV antibody positive and HCV-RNA detected) Systemic active infection requiring antibiotic treatment Congenital or acquired immunodeficiency (e.g., HIV infection) Vaccination with live or attenuated vaccines within 4 weeks prior to intraperitoneal perfusion.\n\nSevere cardiovascular diseases, including:\n\nUncontrolled hypertension (SBP \\> 160 mmHg and\u002For DBP \\> 100 mmHg) History of hypertensive crisis or hypertensive encephalopathy Cardiovascular accident, TIA, myocardial infarction, unstable angina, or significant vascular disease within 6 months NYHA Class ≥ II heart failure or LVEF \\\u003C 50% Severe arrhythmia uncontrolled by medication (QTc ≥ 450 ms for males, ≥ 470 ms for females), or congenital Long QT syndrome Severe respiratory disease (e.g., history of severe interstitial lung disease, severe COPD), FEV1 \\\u003C 2L, or DLCO \\\u003C 40%.\n\nHistory of clear neurological or psychiatric disorders, including epilepsy or dementia.\n\nOther conditions considered unsuitable for the study by the investigator (e.g., prior Grade ≥ 3 adverse events from immunotherapy).","FEMALE",{"count":180,"type":20},29,[182,23],"PHASE1","This is a single-center, open-label, Phase I\u002FII clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of SK-NK Cell Injection administered via intraperitoneal (IP) perfusion in patients with advanced ovarian cancer complicated by massive ascites .\n\nThe study focuses on patients who have failed standard therapies and are suffering from severe ascites. The treatment involves the direct infusion of allogeneic, highly activated Natural Killer (NK) cells (SK-NK) into the abdominal cavity .\n\nThe study consists of two phases:\n\nPhase I (Dose Escalation): To determine the safety profile and the Recommended Phase 2 Dose (RP2D) using a \"3+3\" design with three increasing dose levels.\n\nPhase II (Dose Expansion): To further evaluate the efficacy of the treatment in controlling ascites and suppressing tumor growth at the determined RP2D.\n\nParticipants will receive the study treatment once weekly for 4 weeks.",[185,26],"Ovarian Neoplasms Malignant",[187,188,189,190,191,192,193],"SK-NK Cell Injection","Natural Killer Cells","NK Cell Therapy","Intraperitoneal Perfusion","Adoptive Immunotherapy","Immunotherapy","Massive Ascites","2026-03-13",{"date":196,"type":36},"2026-03-17",{"date":198,"type":36},"2026-01-05",{"date":200,"type":20},"2026-12-31",{"name":202,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":54,"phases":4,"briefSummary":213,"conditions":214,"keywords":217,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":4},"100622955","viatorr-tips-study-evaluating-6-10mm-diameters-viatips-100622955","NCT07390344","VIATORR® TIPS Study Evaluating 6-10mm Diameters (VIATIPS)","VIATIPS","Inclusion Criteria:\n\n1. The subject is eligible for treatment with the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion 6-10mm for de novo TIPS creation.\n2. The subject has cirrhotic portal hypertension.\n3. The subject is ≥18 years of age.\n4. The subject is capable of complying with protocol requirements, including follow up.\n5. The subject or legal representative signed the informed consent form (ICF).\n\nExclusion Criteria:\n\n1. The subject has any portal vein thrombosis, including both occlusive and non-occlusive thrombosis.\n2. The subject has received a liver transplantation. Patients on the transplant list are still eligible.\n3. The subject has a life expectancy of less than 6 months.\n4. The subject has extrahepatic or hepatic malignancy or a history of previous malignancy, unless treated curatively ≥5 years prior to enrollment. Subjects with non-melanoma skin cancer and\u002For carcinoma in situ of the cervix remain eligible.\n5. The subject has inadequate functional hepatic reserve with a Model for End-Stage Liver Disease (MELD) Score of \\> 25 or Child Pugh Score of \\> 14.\n6. The subject is enrolled in another investigational study, unless agreed in advance in writing by the Sponsor.\n7. The subject is pregnant at the time of informed consent signature.\n8. The subject has any other condition which in the judgement of the investigator would preclude adequate Study participation.",{"count":211,"type":20},152,"2 Years","This Registry will look at patients being treated with a transjugular intrahepatic portosystemic shunt (TIPS) procedure for portal hypertension. The purpose of this Registry is to collect data on the safety and performance of the GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion (6-10mm) for 2 years in real world setting.\n\nAdditionally, data will be collected on the safety and performance of the GORE TIPS Set when utilized.",[26,215,216],"Variceal Bleeding","Portal Hypertension Related to Cirrhosis",[151,218,150,219,220],"TIPS","decompensated","Transjugular Intrahepatic Portosystemic Shunt","2026-02-05",{"date":223,"type":36},"2026-02-10",{"date":225,"type":20},"2026-06",{"date":227,"type":20},"2029-09-30",{"name":229,"class":230},"W.L.Gore & Associates","INDUSTRY",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":237,"eligibilityCriteria":238,"healthyVolunteers":11,"sex":16,"minAge":239,"maxAge":17,"enrollmentInfo":240,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":44},"100601693","pediatric-intravenous-contrast-enhanced-ultrasoundceus-in-china-100601693","NCT07113808","Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China","Clinical Medical Quality Control Management of Pediatric Intravenous Contrast-Enhanced Ultrasound(CEUS) in China: A Multi-Center Study","CEUS","Inclusion Criteria:\n\n1. Age 29 days to 18 years old;\n2. The clinical diagnosis was abdominal space-occupying lesions, blunt abdominal trauma, ascites of unknown cause, and children with suspected abdominal disease but other examinations could not identify the cause.\n\nExclusion Criteria:\n\n1. Allergic to sulfur hexafluoride or other components;\n2. Heart disease with right-to-left shunt\u002Fsevere pulmonary hypertension \u002Funcontrolled systemic hypertension\u002Frespiratory failure\u002Fheart failure\u002Fsevere arrhythmia;\n3. Electrocardiogram, echocardiography or clinical manifestations of myocardial ischemia;\n4. Patients with severe blood system diseases or infectious diseases;\n5. Hypercoagulable state and recent history of thrombosis;\n6. Severe hepatic and renal insufficiency;\n7. Patients with respiratory tract infection or congenital respiratory malformation.","29 Days",{"count":241,"type":20},108,"The goal of this clinical trial is to evaluate the application of intravenous contrast-enhanced ultrasound examination in children with intra-abdominal diseases that require clear diagnoses. The main questions it aims to answer are:\n\n* Is intravenous contrast-enhanced ultrasound helpful for the diagnosis of intra-abdominal diseases in children?\n* What medical problems do participants have when participating in intravenous contrast-enhanced ultrasound examination?\n* How can ultrasound doctors conduct intravenous contrast-enhanced ultrasound examinations in a standardized manner? Researchers will performing intravenous contrast-enhanced ultrasound examinations on participants and collecting research subjects to establish a multicenter clinical data database.\n\nParticipants will:\n\n* Perform abdominal ultrasound examination to assess the condition.\n* At least conduct one intravenous contrast-enhanced ultrasound examination. Based on the result of the contrast examination, decide whether to conduct another examination.\n* Keep a diary of their symptoms and therapeutic process in 30 days.",[244,245,26],"Abdominal Neoplasm","Abdominal Injury","2025-12-05",{"date":248,"type":36},"2025-12-08",{"date":250,"type":36},"2024-09-10",{"date":252,"type":20},"2026-09-30",{"name":254,"class":43},"The Children's Hospital of Zhejiang University School of Medicine",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":262,"enrollmentInfo":263,"targetDuration":265,"studyType":54,"phases":4,"briefSummary":266,"conditions":267,"keywords":270,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":44},"100306314","vicis---vienna-cirrhosis-study-100306314","NCT03267615","VICIS - Vienna Cirrhosis Study","VICIS","Inclusion Criteria:\n\n* Age \\>18 years and \\\u003C100 years\n* Diagnosis of advanced chronic liver disease (by liver stiffness ≥10kPa, HVPG\\>5mmHg or Histology F3\u002FF4)\n* Written informed consent\n\nExclusion Criteria:\n\n* Withdrawal of written informed consent","100 Years",{"count":264,"type":20},10000,"10 Years","Patients with advanced chronic liver diseases treated at the Vienna General Hospital of the Medical University of Vienna will be offered to participate in this prospective observational trial - including an optional participation in a biobank.\n\nClinical parameters and laboratory parameters will be recorded for all patients and patients will undergo a regular follow-up schedule with clinical visits at the Vienna General Hospital.\n\nThis study is linked to a biobank with serum\u002Fplasma, ascitic fluid, urine, GI tract mucosal biopsies, liver biopsies and stool collected from the study participants.",[268,146,26,269,144],"Liver Cirrhosis","Variceal Hemorrhage",[268,146],"2025-09-22",{"date":273,"type":36},"2025-09-25",{"date":275,"type":36},"2017-02-01",{"date":277,"type":20},"2027-12-31",{"name":279,"class":43},"Medical University of Vienna",{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":21,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":305},"100324660","medical-economic-evaluation-of-the-care-of-refractory-ascites-by-implantation-of-alfapump-device-in-cirrhotic-patients-100324660","NCT03506893","Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients","ARIAPUMP","Inclusion Criteria:\n\n* Patient with refractory ascites who has had a minimum of 5 paracentesis in the last 3 months.\n* Patient with an estimated life expectancy of at least 6 months on the day of inclusion.\n* Patient with contraindication to the application of a TIPS or who has expressed a refusal of the procedure or a non-functional TIPS\n* Patient affiliated with or in receipt of social security\n* Informed and written consent signed by the patient.\n\nExclusion Criteria:\n\n* Local or systemic infection in the month preceding the procedure\n* Hepatocellular carcinoma with palliative care\n* MELD Score \\> 18\n* Child Pugh C Score \\> 10\n* Creatinine Clearance \\\u003C 50 ml\u002Fmn\n* Digestive hemorrhage or episode of hepatic encephalopathy within two weeks prior to device insertion\n* Contraindication to general anesthesia\n* Contraindication to implant surgery of the device:\n\n  * Obstructive urological impairment\n  * Partitioning of ascites\n  * Coagulopathy\n* Persons referred to in Articles L1121-5 to L1121-8 of the CSP (corresponding to all protected persons: pregnant woman, parturient, breastfeeding mother, person deprived of liberty by judicial or administrative decision, person subject to a legal protection measure).\n* Patient currently participating in other clinical research or who participated in a clinical trial within one month prior to inclusion.",{"count":288,"type":20},90,[108],"The hypothesis is that the Alfapump® strategy would be more effective in terms of QALYs generated , and that the cost of Alfapump® device and its implantation will be totally or partially offset by the reduction in the number of evacuating parentheses performed and the reduction in the number of complications in patients with refractory ascites awaiting liver transplantation or not. On the other hand, given the difference in the clinical profiles of these two populations (whether or not they are awaiting transplantation), these two populations will be study separately\n\nEvaluation of the medical-economic impact at 1 year of the two therapeutic strategies: implantation of Alfapump® versus repeated evacuating paracentesis in cirrhotic patients with refractory ascites without scheduled liver transplantation.",[26,292,142],"Paracentesis",[294,295],"refractory ascite","pump system","2025-03-25",{"date":298,"type":36},"2025-03-30",{"date":300,"type":36},"2018-07-17",{"date":302,"type":20},"2027-05-31",{"name":304,"class":43},"University Hospital, Grenoble",10,{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100566661","drug-sensitivity-of-hydrothorax-and-ascite-organoids-from-breast-cancer-100566661","NCT06658080","Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer","Drug Sensitivity Based on Hydrothorax and Ascite Organoids Derived from Metastasic Breast Cancer","Inclusion Criteria:\n\n1. Signed informed consent form and willingness to participate in the clinical study.\n2. patients aged between 18 and 70 years old.\n3. Confirmed metastatic breast cancer patients with hydrothorax and ascite fluid, which was verified to contain tumor cells by lab.\n4. ECOG performance status score of 0-1.\n5. No significant abnormalities in liver and kidney function (BIL \\\u003C1.5-fold upper limit of normal (ULN)；ALT\\\u003C2.5×ULN; AST\\\u003C2.5×ULN；Crea≤1×ULN).\n\nExclusion Criteria:\n\n1.Patients not suitable for chemotherapy and target therapy","70 Years",{"count":288,"type":20},"Malignant hydrothorax and ascitic fluid in advanced breast cancer often arise from metastasis to the lungs, pleura, or liver. Patients with this condition experience rapid disease progression and multidrug resistance, facing limited treatment options. Clinical guidelines offer various therapies based on molecular subtypes; however, their effectiveness can be hindered by prior treatments, patient health, and tumor evolution. Current evaluations of treatment efficacy typically take two cycles, delaying the recognition of ineffective therapies and resulting in unnecessary side effects and costs. Organoid models present a promising solution, accurately replicating tumor structure and cellular diversity compared to traditional methods. These patient-derived models facilitate improved drug sensitivity testing, leading to more personalized treatment plans. In this study, 90 patients diagnosed with metastatic breast cancer accompanied by hydrothorax and ascitic fluid will be recruited. Patient-derived organoids will be used to assess the sensitivity of chemotherapy regimens, including Doxorubicin, Carboplatin, Cyclophosphamide, and Paclitaxel, along with targeted therapies such as Herceptin and Pertuzumab.",[317,318,26,319,320],"Breast Cancer Metastatic","Hydrothorax","Organoids","Drug Evaluation","2025-01-05",{"date":323,"type":36},"2025-01-07",{"date":325,"type":36},"2024-11-09",{"date":327,"type":20},"2027-10-25",{"name":329,"class":43},"Second Affiliated Hospital, School of Medicine, Zhejiang University",3,{"id":332,"slug":333,"hasResults":11,"nctId":334,"briefTitle":335,"officialTitle":336,"acronym":4,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":178,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":44},"100558639","high-definition-profiling-of-ovarian-cancer-ascites-100558639","NCT06553742","High Definition Profiling of Ovarian Cancer Ascites","High Definition Profiling of Ovarian Cancer Ascites for the Identification of Prognostic Biomarkers and Immunotherapeutic Targets: an Integrative Cell of Origin-guided Approach","Inclusion Criteria:\n\n* Patients with suspicious or confirmed ovarian cancer pathology undergoing debulking surgery\n* Diagnosis of high grade serous ovarian cancer confirmed by histopathology assessment\n* Patients who provided written informed consent\n\nExclusion Criteria:\n\n* HIV-positive patients\n* HBV-positive patients\n* HCV-positive patients",{"count":339,"type":20},50,"This project entails the collection of a prospective cohort of ascites (AS) samples from High Grade Serous Ovarian Cancer (HGSOC) patients.\n\nHigh Grade Serous Ovarian Cancer (HGSOC) is a major cause of cancer-related mortality, due to the late-stage diagnosis and failure of surgery and chemotherapy (CHT) to eradicate the disease with no significant improvement in overall survival.\n\nThe primary objective of the project is to generate a comprehensive map of ascites cell components, detailing both their intrinsic features and the landscape of cellular interactions mediated by soluble factors in ascitic fluid.",[342,343,26],"Ovarian Cancer","High Grade Ovarian Serous Adenocarcinoma","2024-11-18",{"date":346,"type":36},"2024-11-20",{"date":348,"type":20},"2024-11",{"date":350,"type":20},"2033-12",{"name":352,"class":43},"European Institute of Oncology",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":11,"sex":178,"minAge":17,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":44},"100441248","13c-glucose-tracing-of-tumour-and-t-cells-in-the-ascites-of-ovarian-cancer-patients-100441248","NCT05025878","13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.","Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients","iMETABO","Inclusion Criteria:\n\n* Ovarian cancer\n* Any stage or grade of disease\n* Ascites fluid that requires draining\n* Any treatment regimen\n* Primary or recurrent ascites\n* Understands the concept of the study and give informed consent.\n\nExclusion Criteria:\n\n* Participants must not have diabetes or abnormal hemoglobin A1C levels.\n* The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada.\n* Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.",{"count":305,"type":20},"The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \\[U-13C\\]glucose into patients during standard paracentesis.",[342,26],"2024-08-08",{"date":366,"type":36},"2024-08-09",{"date":368,"type":36},"2021-10-20",{"date":370,"type":20},"2024-08",{"name":372,"class":43},"British Columbia Cancer Agency",{"id":374,"slug":375,"hasResults":11,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":381,"maxAge":4,"enrollmentInfo":382,"targetDuration":384,"studyType":54,"phases":4,"briefSummary":385,"conditions":386,"keywords":391,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":44},"100421450","cirrhosis-registry-of-hospitalized-patients-100421450","NCT04767945","Cirrhosis Registry of Hospitalized Patients","Registry of Adult Consenting Patients Admitted to the Liver Unit With Liver Cirrhosis","RH7","Inclusion Criteria:\n\n* liver cirrhosis (primarily on clinical grounds)\n* decompensating event leading to hospital admission\n* informed consent\n\nExclusion Criteria:\n\n* declined consent","19 Years",{"count":383,"type":20},2000,"15 Years","Cirrhosis registry of consecutive adult consenting patients hospitalized with liver cirrhosis in the tertiary liver unit",[387,388,26,389,390],"Cirrhosis, Liver","Frailty","Encephalopathy","Infection",[142,392,393],"decompensation","frailty","2022-08-02",{"date":396,"type":36},"2022-08-03",{"date":398,"type":36},"2014-07-01",{"date":400,"type":20},"2029-12-31",{"name":402,"class":43},"F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica"]